Repligen (RGEN) Free Cash Flow Growth (3y) (2013 - 2026)
Powered by 
Analysis
Repligen (RGEN) Free Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 241.68 Bn | 237.61 Bn | 8.34 Bn | 10.07% |
| 2 | Danaher | 147.34 Bn | 142.99 Bn | 3.61 Bn | -7.47% |
| 3 | Agilent Technologies | 43.34 Bn | 41.59 Bn | 1.04 Bn | -3.00% |
| 4 | Illumina | 34.58 Bn | 33.41 Bn | 770.00 Mn | 40.54% |
| 5 | Revvity | 16.31 Bn | 15.29 Bn | 416.87 Mn | 46.57% |
| 6 | Bio-Techne | 11.28 Bn | 11.01 Bn | 211.39 Mn | 6.21% |
| 7 | Bio-Rad Laboratories | 10.16 Bn | 8.54 Bn | 345.80 Mn | 1.68% |
| 8 | Repligen | 9.77 Bn | 8.75 Bn | 110.04 Mn | 1.51% |
| 9 | 10x Genomics | 9.45 Bn | 8.90 Bn | 112.50 Mn | 50.78% |
| 10 | Bruker | 9.26 Bn | 9.04 Bn | 416.00 Mn | -116.26% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.51% |
| Mar 31, 2026 | 107.37% |
| Dec 31, 2025 | -24.90% |
| Sep 30, 2025 | 13.66% |
| Jun 30, 2025 | 1.86% |
| Mar 31, 2025 | 68.65% |
| Dec 31, 2024 | 24.33% |
| Sep 30, 2024 | 54.00% |
| Jun 30, 2024 | 20.89% |
| Mar 31, 2024 | 178.80% |
| Dec 31, 2023 | 72.82% |
| Sep 30, 2023 | 20.31% |
| Jun 30, 2023 | 24.56% |
| Mar 31, 2023 | -21.19% |
| Dec 31, 2022 | 57.61% |
| Sep 30, 2022 | 21.69% |
| Jun 30, 2022 | 13.20% |
| Mar 31, 2022 | -36.28% |
| Dec 31, 2021 | 97.03% |
| Sep 30, 2021 | -11.50% |